메뉴 건너뛰기




Volumn 31, Issue 29, 2013, Pages

Ruxolitinib withdrawal syndrome leading to tumor lysis

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CREATININE; ENZYME; ERGOCALCIFEROL; HEMOGLOBIN; HYDROXYUREA; INSULIN; LACTATE HYDROGENASE; METRONIDAZOLE; PEGINTERFERON; PHOSPHORUS; POLYSTYRENESULFONATE SODIUM; POTASSIUM; PREDNISONE; RASBURICASE; RETICULIN; RUXOLITINIB; UNCLASSIFIED DRUG; URIC ACID; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

EID: 84891533281     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.6473     Document Type: Short Survey
Times cited : (25)

References (10)
  • 2
    • 77956696835 scopus 로고    scopus 로고
    • Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis
    • Verstovsek S, Kantarjian H, Mesa RA, et al: Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117-1127, 2010
    • (2010) N Engl J Med , vol.363 , pp. 1117-1127
    • Verstovsek, S.1    Kantarjian, H.2    Mesa, R.A.3
  • 3
    • 84863393110 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
    • Verstovsek S, Mesa RA, Gotlib J, et al: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799-807, 2012
    • (2012) N Engl J Med , vol.366 , pp. 799-807
    • Verstovsek, S.1    Mesa, R.A.2    Gotlib, J.3
  • 4
    • 84857837774 scopus 로고    scopus 로고
    • JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
    • Harrison C, Kiladjian JJ, Al-Ali HK, et al: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787-798, 2012
    • (2012) N Engl J Med , vol.366 , pp. 787-798
    • Harrison, C.1    Kiladjian, J.J.2    Al-Ali, H.K.3
  • 5
    • 80054028202 scopus 로고    scopus 로고
    • Long-term outcome of treatment with ruxolitinib in myelofibrosis
    • Tefferi A, Litzow MR, Pardanani A: Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 365:1455-1457, 2011
    • (2011) N Engl J Med , vol.365 , pp. 1455-1457
    • Tefferi, A.1    Litzow, M.R.2    Pardanani, A.3
  • 6
    • 83155182714 scopus 로고    scopus 로고
    • Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis
    • Tefferi A, Pardanani A: Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 86:1188-1191, 2011
    • (2011) Mayo Clin Proc , vol.86 , pp. 1188-1191
    • Tefferi, A.1    Pardanani, A.2
  • 7
    • 78049446139 scopus 로고    scopus 로고
    • Bilateral ureteral obstruction due to primary myelofibrosis caused hyperuricaemia
    • Cvetković ZP, Cvetković BR, Celeketić D, et al: Bilateral ureteral obstruction due to primary myelofibrosis caused hyperuricaemia. Acta Chir Iugosl 57:79-83, 2010
    • (2010) Acta Chir Iugosl , vol.57 , pp. 79-83
    • Cvetković, Z.P.1    Cvetković, B.R.2    Celeketić, D.3
  • 8
    • 0347712028 scopus 로고    scopus 로고
    • Acute renal failure secondary to spontaneous acute tumor lysis syndrome in myelofibrosis
    • Sile S, Wall BM: Acute renal failure secondary to spontaneous acute tumor lysis syndrome in myelofibrosis. Am J Kidney Dis 38:E21, 2001
    • (2001) Am J Kidney Dis , vol.38
    • Sile, S.1    Wall, B.M.2
  • 9
    • 78149497051 scopus 로고    scopus 로고
    • Tumour lysis syndrome after splenic irradiation in a patient with JAK2 V617F post-polycythaemia vera myelofibrosis
    • Jain S, Harrison C, McMullin MF, et al: Tumour lysis syndrome after splenic irradiation in a patient with JAK2 V617F post-polycythaemia vera myelofibrosis. Clin Oncol (R Coll Radiol) 22:893, 2010
    • (2010) Clin Oncol (R Coll Radiol) , vol.22 , pp. 893
    • Jain, S.1    Harrison, C.2    McMullin, M.F.3
  • 10
    • 59649097568 scopus 로고    scopus 로고
    • The role of hypercytokinemia in the pathophysiology of tumor lysis syndrome (TLS) and the treatment with continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter (PMMA-CHDF)
    • Nakamura M, Oda S, Sadahiro T, et al: The role of hypercytokinemia in the pathophysiology of tumor lysis syndrome (TLS) and the treatment with continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter (PMMA-CHDF). Transfus Apher Sci 40:41-47, 2009
    • (2009) Transfus Apher Sci , vol.40 , pp. 41-47
    • Nakamura, M.1    Oda, S.2    Sadahiro, T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.